{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:00:49Z","timestamp":1781715649440,"version":"3.54.5"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,10,15]]},"DOI":"10.2169\/internalmedicine.8993-21","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T22:10:29Z","timestamp":1647036629000},"page":"3077-3081","source":"Crossref","is-referenced-by-count":3,"title":["Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria"],"prefix":"10.2169","volume":"61","author":[{"given":"Shinji","family":"Kume","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Yasuda-Yamahara","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Imamura-Uehara","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kuwagata","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yamahara","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takeda","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Chin-Kanasaki","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Maegawa","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167, 1967.","DOI":"10.1056\/NEJM196705252762101"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science 167: 1268-1269, 1970.","DOI":"10.1126\/science.167.3922.1268"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105: 2812-2817, 2008.","DOI":"10.1073\/pnas.0712309105"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 13: S134-S138, 2002.","DOI":"10.1097\/01.ASN.0000016684.07368.75"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wanner C, Oliveira JP, Ortiz A, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5: 2220-2228, 2010.","DOI":"10.2215\/CJN.04340510"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Najafian B, T\u00f8ndel C, Svarstad E, et al. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol 31: 865-875, 2020.","DOI":"10.1681\/ASN.2019050497"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9-16, 2001.","DOI":"10.1056\/NEJM200107053450102"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yokoyama T, Manabe S, Horita S, et al. The origin of urinary mulberry cells in Fabry disease. Kidney Int 99: 1246, 2021.","DOI":"10.1016\/j.kint.2020.08.019"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146: 77-86, 2007.","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946, 2002.","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rob D, Marek J, Dost\u00e1lov\u00e1 G, et al. Uric acid as a marker of mortality and morbidity in Fabry disease. PLoS One 11: e0166290, 2016.","DOI":"10.1371\/journal.pone.0166290"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Maejima I, Takahashi A, Omori H, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J 32: 2336-2347, 2013.","DOI":"10.1038\/emboj.2013.171"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/20\/61_8993-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T03:26:37Z","timestamp":1665804397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/20\/61_8993-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":12,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8993-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"article-number":"8993-21"}}